Condition: Prostate Cancer · Prostate Cancer Recurrent · Prostate Cancer Metastatic · Sponsor: Universitaire Ziekenhuizen KU Leuven
The aim is to investigate whether the addition of short-term androgen deprivation therapy (ADT) during 1 month or short-term ADT during 6 months together with an androgen receptor targeted therapy (ARTA) to metastasis-directed therapy (MDT) significantly prolongs poly-metastatic free survival (PMFS) and/or metastatic castration-refractory prostate cancer free survival (mCRPC-FS) in patients with oligorecurrent hormone sensitive prostate cancer.
This description comes directly from the study's public registry record.
Kato Rans, MD · 003216340110 · kato.rans@uzleuven.be
Gert De Meerleer, MD, PhD · 003216347600 · gert.demeerleer@uzleuven.be
Always discuss trial participation with your own doctor first.
| University Hospitals Leuven | Leuven, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05352178